Elevance Health, Inc. $ELV Stock: Boston Partners Increases Position

Boston Partners increased its holdings in Elevance Health, Inc. (NYSE:ELV – Free Report) by 2.5% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 140,857 shares of the company’s stock after purchasing an additional 3,450 shares during the period. Boston Partners’ holdings in Elevance Health were worth $54,791,000 as of its most recent SEC filing.

A number of other institutional investors have also recently added to or reduced their stakes in ELV. BlackRock Inc. acquired a new stake in shares of Elevance Health during the second quarter valued at about $7,344,424,000. State Street Corp boosted its stake in Elevance Health by 1.3% in the second quarter. State Street Corp now owns 10,426,610 shares of the company’s stock valued at $4,032,283,000 after acquiring an additional 137,914 shares during the period. Wellington Management Group LLP grew its holdings in shares of Elevance Health by 12.0% during the second quarter. Wellington Management Group LLP now owns 9,213,513 shares of the company’s stock valued at $3,563,142,000 after purchasing an additional 984,976 shares during the last quarter. First Eagle Investment Management LLC raised its position in shares of Elevance Health by 1.4% during the 2nd quarter. First Eagle Investment Management LLC now owns 4,188,196 shares of the company’s stock worth $1,619,701,000 after purchasing an additional 55,905 shares during the period. Finally, Bank of New York Mellon Corp bought a new stake in shares of Elevance Health in the 2nd quarter worth approximately $1,246,349,000. 89.24% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on ELV. Wells Fargo & Company upped their price target on shares of Elevance Health from $473.00 to $492.00 and gave the stock an “overweight” rating in a research note on Tuesday, October 27th. Wall Street Zen raised shares of Elevance Health from a “hold” rating to a “buy” rating in a research report on Saturday, November 7th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Elevance Health in a report on Wednesday, November 11th. Royal Bank Of Canada increased their price target on shares of Elevance Health from $424.00 to $455.00 and gave the stock a “sector perform” rating in a research report on Thursday, October 22nd. Finally, TD Cowen lifted their price objective on Elevance Health from $465.00 to $495.00 and gave the company a “buy” rating in a research report on Friday, October 23rd. Sixteen investment analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the company. According to MarketBeat.com, Elevance Health presently has a consensus rating of “Moderate Buy” and a consensus target price of $458.91.

View Our Latest Research Report on ELV

Insider Activity at Elevance Health

In other news, CFO Mark Kaye sold 10,584 shares of the business’s stock in a transaction that occurred on Thursday, October 22nd. The stock was sold at an average price of $440.13, for a total value of $4,658,335.92. Following the sale, the chief financial officer directly owned 19,919 shares of the company’s stock, valued at $8,766,949.47. The trade was a 34.70% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Ramiro G. Peru acquired 1,000 shares of Elevance Health stock in a transaction that occurred on Thursday, November 19th. The shares were purchased at an average price of $383.86 per share, with a total value of $383,860.00. Following the transaction, the director owned 11,908 shares of the company’s stock, valued at $4,571,004.88. The trade was a 9.17% increase in their position. The disclosure for this purchase is available in the SEC filing. 0.34% of the stock is currently owned by company insiders.

Elevance Health Stock Up 1.1%

NYSE ELV opened at $394.40 on Friday. The company has a 50 day moving average of $415.92 and a 200-day moving average of $376.97. The company has a current ratio of 1.47, a quick ratio of 1.47 and a debt-to-equity ratio of 0.68. Elevance Health, Inc. has a 1-year low of $274.84 and a 1-year high of $450.69. The company has a market cap of $85.21 billion, a price-to-earnings ratio of 14.70, a PEG ratio of 2.13 and a beta of 0.63.

Elevance Health (NYSE:ELV – Get Free Report) last issued its quarterly earnings results on Wednesday, October 21st. The company reported $6.99 EPS for the quarter, topping analysts’ consensus estimates of $4.71 by $2.28. Elevance Health had a net margin of 2.55% and a return on equity of 14.97%. The company had revenue of $50.44 billion for the quarter, compared to analyst estimates of $49.28 billion. During the same quarter in the previous year, the business earned $6.03 earnings per share. Elevance Health’s revenue was up .7% compared to the same quarter last year. On average, equities research analysts expect that Elevance Health, Inc. will post 29.16 earnings per share for the current fiscal year.

Elevance Health Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, December 18th. Shareholders of record on Friday, December 4th will be given a dividend of $1.72 per share. The ex-dividend date is Friday, December 4th. This represents a $6.88 annualized dividend and a yield of 1.7%. Elevance Health’s payout ratio is presently 29.34%.

Elevance Health Company Profile

(Free Report)

Elevance Health, Inc. is a U.S. health benefits and services company. Formerly known as Anthem, Inc., it adopted the Elevance Health name in 2022 while retaining the Anthem brand for many of its health plans. The company offers medical, pharmacy, dental, vision and behavioral health coverage, including plans for individuals and employers as well as programs serving Medicare and Medicaid members. Its services also include care management, pharmacy benefit services and other health-related capabilities through its Carelon business.

Further Reading

Want to see what other hedge funds are holding ELV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Elevance Health, Inc. (NYSE:ELV – Free Report).

Institutional Ownership by Quarter for Elevance Health (NYSE:ELV)

Receive News & Ratings for Elevance Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elevance Health and related companies with MarketBeat.com's FREE daily email newsletter.